Not yet recruiting
A Phase III study of AZD0120 with drug combination versus standard therapy in adults with newly diagnosed multiple myeloma not eligible for stem cell transplant
Not yet recruitingRegistered drugNo placebo
A Phase III study of AZD0120 with drug combination versus standard therapy in adults with newly diagnosed multiple myeloma not eligible for stem cell transplant
Registered drugNo placebo
- Substances:AZD0120Bortezomib+4
Countries:
Poland
Poland- Participants:18–64 years · 65+ years
- Substances:AZD0120
